Moreover, previous studies have shown that the loss of ATRX increases sensitivity to DNA-damaging agents [39], suggesting that ATRX mutations may represent a crucial point of therapeutic intervention for high-grade NF1 gliomas and LGm6 sporadic gliomas [37,40,41]. This evidence concerns the gene ATRX and neurofibromatosis type 1.